Translational Breast Cancer Research,
Год журнала:
2024,
Номер
5, С. 30 - 30
Опубликована: Окт. 1, 2024
Human
epidermal
growth
factor
receptor
2
(HER2)-low
breast
cancer
is
a
newly
identified
targetable
subset
of
tumors,
and
its
clinical
characteristics
treatment
strategies
are
controversial.
The
emergence
novel
anti-HER2
antibody-drug
conjugate
(ADC)
has
brought
promising
approaches
for
HER2-low
treatment.
Several
trials
have
validated
the
efficacy
safety
trastuzumab
deruxtecan
(T-Dxd)
in
at
different
settings.
timing,
candidate
identification,
long-term
management,
overcoming
drug
resistance
crucial
questions
to
improve
patient
survival.
Here
we
present
case
hormone
receptor-positive
(HR
Translational Cancer Research,
Год журнала:
2024,
Номер
13(4), С. 1773 - 1785
Опубликована: Апрель 1, 2024
The
recently
developed
anti-human
epidermal
growth
factor
receptor
2
(HER2)
therapy
has
substantially
improved
the
prognosis
of
HER2-positive
breast
cancer.
DESTINY-Breast04
trial
results
showed
that
trastuzumab
deruxtecan
(T-DXd)
significantly
prolonged
survival
patients
with
HER2-low
cancer,
thus
presenting
a
paradigm
shift
in
anti-HER2
therapy.
This
may
facilitate
change
treatment
strategy
for
However,
implication
hormone
(HR)-positive
cancer
is
unclear.
In
this
retrospective
study,
we
aimed
to
reveal
association
between
HER2
status,
namely
and
HER2-zero,
HR-positive
Therapeutic Advances in Medical Oncology,
Год журнала:
2024,
Номер
16
Опубликована: Янв. 1, 2024
Among
women,
breast
cancer
is
the
most
prevalent
form
of
a
malignant
tumour.
subtypes
cancer,
hormone
receptor
(HR)
positive
and
human
epidermal
growth
factor
(HER2)
negative
kinds
make
up
biggest
proportion.
The
advent
cyclin-dependent
kinase
4
6
(CDK4/6)
inhibitors,
which
are
dependent
on
cell
cycle
proteins,
has
greatly
enhanced
prognosis
patients
with
advanced
HR+/HER2−
cancer.
This
specific
treatment
that
stops
cells
by
preventing
them
from
dividing.
Nevertheless,
drug
resistance
disease
unavoidably
impacts
effectiveness
patients.
report
provides
thorough
analysis
current
research
advancements
about
mechanism
CDK4/6
inhibitors
in
It
presents
an
in-depth
discussion
numerous
viewpoints,
such
as
aberrant
regulation
changes
signalling
pathways.
In
response
to
problem,
subsequent
strategies
also
being
explored,
including
switching
other
inhibitor
drugs,
combination
novel
endocrine
therapeutic
agents,
optimal
targeted
therapies
chemotherapy.
An
study
can
assist
identifying
creative
tactics
overcome
or
postpone
resistance,
alleviate
problem
restricted
following
enhance
Translational Breast Cancer Research,
Год журнала:
2024,
Номер
5, С. 30 - 30
Опубликована: Окт. 1, 2024
Human
epidermal
growth
factor
receptor
2
(HER2)-low
breast
cancer
is
a
newly
identified
targetable
subset
of
tumors,
and
its
clinical
characteristics
treatment
strategies
are
controversial.
The
emergence
novel
anti-HER2
antibody-drug
conjugate
(ADC)
has
brought
promising
approaches
for
HER2-low
treatment.
Several
trials
have
validated
the
efficacy
safety
trastuzumab
deruxtecan
(T-Dxd)
in
at
different
settings.
timing,
candidate
identification,
long-term
management,
overcoming
drug
resistance
crucial
questions
to
improve
patient
survival.
Here
we
present
case
hormone
receptor-positive
(HR
